BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20410237)

  • 1. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
    Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
    Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
    Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
    Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MATRICS consensus cognitive battery: what we know 6 years later.
    Green MF; Harris JG; Nuechterlein KH
    Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
    [No Abstract]   [Full Text] [Related]  

  • 4. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
    Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
    Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
    Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug initiatives to improve cognitive function.
    Marder SR
    J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
    Marder SR; Fenton W
    Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
    Keefe RS; Buchanan RW; Marder SR; Schooler NR; Dugar A; Zivkov M; Stewart M
    Schizophr Bull; 2013 Mar; 39(2):417-35. PubMed ID: 22114098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement and Treatment Research toImprove Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version.
    Kaneda Y; Ohmori T; Okahisa Y; Sumiyoshi T; Pu S; Ueoka Y; Takaki M; Nakagome K; Sora I
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):182-8. PubMed ID: 23581870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
    Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
    Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NIMH-MATRICS consensus statement on negative symptoms.
    Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR
    Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659
    [No Abstract]   [Full Text] [Related]  

  • 17. The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties.
    Jędrasik-Styła M; Ciołkiewicz A; Styła R; Linke M; Parnowska D; Gruszka A; Denisiuk M; Jarema M; Green MF; Wichniak A
    Psychiatr Q; 2015 Sep; 86(3):435-47. PubMed ID: 25601030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.
    Georgiades A; Davis VG; Atkins AS; Khan A; Walker TW; Loebel A; Haig G; Hilt DC; Dunayevich E; Umbricht D; Sand M; Keefe RSE
    Schizophr Res; 2017 Dec; 190():172-179. PubMed ID: 28433500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
    Bromley E
    Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
    Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
    Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.